Daxiang Biotech is a leading innovator in organoid-on-a-chip technologies in China and a global provider of integrated microphysiological systems (MPS) solutions for drug discovery, translational research, and precision medicine. Founded in 2018, the company has established a fully integrated, end-to-end platform spanning design, modeling, R&D, manufacturing, and application of human-relevant in vitro systems. Powered by its core technology framework—Organoid-on-a-Chip + AI + Automation—Daxiang develops proprietary instruments, chips, reagents, and advanced human-relevant models to help global life sciences partners improve preclinical decision-making and accelerate development timelines. At the core of its technology is the IBAC® (Integrated Biomimetic Array Chip) platform, which integrates stem cell biology, organoid science, and microfluidics to recreate physiologically relevant human tissue environments in vitro. Based on this platform, Daxiang has developed 50+ organoid culture kits and 100+ humanized physiological and disease models across oncology, liver, gastrointestinal, kidney, brain, and cardiovascular applications. Daxiang’s technologies have been validated by third-party institutions and adopted by leading pharmaceutical companies, biotechnology companies, hospitals, and research institutes. The company has supported multiple IND-enabling programs, helping partners improve translational predictability and reduce reliance on animal models in selected applications. Daxiang Biotech is actively seeking global partnerships with pharmaceutical and biotech companies, CRO/CDMO organizations, research institutions, distributors, and strategic investors. Key collaboration interests include drug discovery services, translational model co-development, precision medicine applications, regional commercialization, and AI-enabled next-generation preclinical platforms.
Cytomos
Cytomos is a cutting edge biotool company revolutionising predictive cell analytics, using the physics of the cell to predict biology. Our proprietary platform, Celledonia® powered by AuraCyt® uniquely predicts cell behaviour by capturing a digital fingerprint of every cell — delivering rapid, high-resolution insights into cell health, phenotype, and function. Celledonia® offers intrinsic, label-free cell analysis at the press of a button, enabling faster, more reliable decisions across research, development, and manufacturing, unveiling a new dimension of cellular understanding. Cytomos provides technology that accelerates discovery, development and scale-up in areas including advanced therapies, cell line development, immunotherapies, differentiation competent cells and biologics. Our mission is to redefine how we understand and control living cells. Celledonia® is a benchtop cell analyser which detects cell features for which there are no biomarkers and provides predictive insights into how those cells will behave during processing. In short, it lets you see what’s coming — before it happens. That predictive power has huge implications for biomanufacturing: faster process optimisation, improved product consistency, and a deeper understanding of what drives cellular performance, quickly. We don’t simply hand over the technology and wish you luck; we work alongside you, integrating the system into your processes to ensure you see the full benefits. We have a dedicated team of scientists and data analysts at our Edinburgh laboratories, who collaborate closely with your teams both in the lab and remotely. Our goal is to make this revolutionary technology both accessible and impactful.
Coherence Biotech Co. Ltd.
Coherence Bio is a lab automation company developing tools to accelerate AI based drug discovery, through end-to-end automation of cell-based testing.